Daniel C. Cho

3.3k total citations · 1 hit paper
61 papers, 1.7k citations indexed

About

Daniel C. Cho is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Daniel C. Cho has authored 61 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Daniel C. Cho's work include Renal cell carcinoma treatment (28 papers), Cancer Immunotherapy and Biomarkers (28 papers) and CAR-T cell therapy research (9 papers). Daniel C. Cho is often cited by papers focused on Renal cell carcinoma treatment (28 papers), Cancer Immunotherapy and Biomarkers (28 papers) and CAR-T cell therapy research (9 papers). Daniel C. Cho collaborates with scholars based in United States, United Kingdom and Spain. Daniel C. Cho's co-authors include Michael B. Atkins, David F. McDermott, Chiara Battelli, James W. Mier, Toni K. Choueiri, Igor Puzanov, David J. Panka, Sabina Signoretti, Ulka N. Vaishampayan and Elizabeth R. Plimack and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer.

In The Last Decade

Daniel C. Cho

61 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

2018 274 citations Michael B. Atkins, Elizabeth R. Plimack et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel C. Cho United States	21	881	851	805	381	336	61	1.7k
Soji Kakiuchi Japan	21	850 1.0×	998 1.2×	910 1.1×	313 0.8×	153 0.5×	41	1.9k
Liza C. Villaruz United States	23	1.3k 1.4×	675 0.8×	1.2k 1.5×	422 1.1×	228 0.7×	81	2.0k
Ana Giménez‐Capitán Spain	22	930 1.1×	954 1.1×	879 1.1×	592 1.6×	171 0.5×	77	1.9k
Ramon Andrade de Mello Portugal	21	745 0.8×	477 0.6×	565 0.7×	314 0.8×	202 0.6×	89	1.4k
Luiz H. Araujo Brazil	13	845 1.0×	446 0.5×	597 0.7×	391 1.0×	200 0.6×	69	1.4k
Zehang Jiang China	10	723 0.8×	534 0.6×	479 0.6×	392 1.0×	365 1.1×	16	1.3k
Sheryl K. Elkin United States	15	498 0.6×	817 1.0×	446 0.6×	280 0.7×	230 0.7×	22	1.5k
Erzsébet Juhász Hungary	15	1.2k 1.3×	568 0.7×	1.1k 1.3×	235 0.6×	201 0.6×	28	1.7k
Georgy M. Manikhas Russia	11	1.4k 1.6×	608 0.7×	1.1k 1.3×	238 0.6×	190 0.6×	35	2.0k
Caicun Zhou China	25	1.4k 1.6×	389 0.5×	1.3k 1.6×	360 0.9×	259 0.8×	39	2.0k

Countries citing papers authored by Daniel C. Cho

Since Specialization

Citations

This map shows the geographic impact of Daniel C. Cho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Cho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Cho more than expected).

Fields of papers citing papers by Daniel C. Cho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel C. Cho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Cho. The network helps show where Daniel C. Cho may publish in the future.

Co-authorship network of co-authors of Daniel C. Cho

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel C. Cho. A scholar is included among the top collaborators of Daniel C. Cho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel C. Cho. Daniel C. Cho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Münster, Pamela N., Nicholas Iannotti, Daniel C. Cho, et al.. (2023). Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Research Communications. 3(12). 2572–2584. 5 indexed citations

McDermott, David F., Jae‐Lyun Lee, Georg A. Bjarnason, et al.. (2021). Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1020–1028. 90 indexed citations

Atkins, Michael B., Elizabeth R. Plimack, Igor Puzanov, et al.. (2021). Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. European Journal of Cancer. 145. 1–10. 21 indexed citations

Martini, Jean-François, Elizabeth R. Plimack, Toni K. Choueiri, et al.. (2020). Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 26(21). 5598–5608. 16 indexed citations

Shapiro, Geoffrey I., Patricia LoRusso, Daniel C. Cho, et al.. (2020). A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. Investigational New Drugs. 39(1). 163–174. 23 indexed citations

Atkins, Michael B., Elizabeth R. Plimack, Igor Puzanov, et al.. (2018). Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. The Lancet Oncology. 19(3). 405–415. 274 indexed citations breakdown →

Cho, Daniel C., Amit Mahipal, Afshin Dowlati, et al.. (2018). Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).. Journal of Clinical Oncology. 36(15_suppl). 8517–8517. 29 indexed citations

Diab, Adi, Nizar M. Tannir, Chantale Bernatchez, et al.. (2017). A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 35(15_suppl). e14040–e14040. 9 indexed citations

Cho, Daniel C.. (2014). Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook. BioDrugs. 28(4). 373–381. 19 indexed citations

10.

Cho, Daniel C. & James W. Mier. (2013). Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma. Current Cancer Drug Targets. 13(2). 126–142. 14 indexed citations

11.

Cho, Daniel C., Thomas E. Hutson, Wolfram E. Samlowski, et al.. (2012). Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy. Cancer. 118(24). 6055–6062. 36 indexed citations

12.

Dabydeen, Donnette, Jyothi P. Jagannathan, Nikhil H. Ramaiya, et al.. (2012). Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome. European Journal of Cancer. 48(10). 1519–1524. 76 indexed citations

13.

Cho, Daniel C., et al.. (2012). Perifosine in renal cell carcinoma. Expert Opinion on Investigational Drugs. 22(2). 285–291. 8 indexed citations

14.

Battelli, Chiara & Daniel C. Cho. (2011). mTOR inhibitors in renal cell carcinoma. Therapy. 8(4). 359–367. 89 indexed citations

15.

Pandya, Shuchi S., James W. Mier, David F. McDermott, & Daniel C. Cho. (2011). Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. British Journal of Urology. 108(8b). E245–9. 5 indexed citations

16.

Cho, Daniel C. & Michael B. Atkins. (2011). Future Directions in Renal Cell Carcinoma: 2011 and Beyond. Hematology/Oncology Clinics of North America. 25(4). 917–935. 18 indexed citations

17.

Cho, Daniel C., David J. Panka, Michael P. Collins, et al.. (2010). The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clinical Cancer Research. 16(14). 3628–3638. 154 indexed citations

18.

Choueiri, Toni K., Meredith M. Regan, Jonathan E. Rosenberg, et al.. (2010). Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy. British Journal of Urology. 106(6). 772–778. 71 indexed citations

19.

Cho, Daniel C., Igor Puzanov, Meredith M. Regan, et al.. (2009). Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy. 32(2). 181–185. 35 indexed citations

20.

Panka, David J., Daniel C. Cho, Michael B. Atkins, & James W. Mier. (2007). GSK-3β Inhibition Enhances Sorafenib-induced Apoptosis in Melanoma Cell Lines. Journal of Biological Chemistry. 283(2). 726–732. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact